MGNX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Macrogenics Inc had $150M of revenue in fiscal 2025, down 0.3% on the year before. Over five years, revenue changed +7.3% a year on average.
Last close Β· Oct 23, 2026
$2.25
38.0%Hi! I read Macrogenics Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β0.3%
No. Sales fell 0.3% last year.
Does it make a profit?
β49.9%
No. It lost money last year.
Does profit turn into cash?
β55.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Macrogenics Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 11, 2026
Wednesday Β· in 16 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 13, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 9, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 12, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 13, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 20, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 5, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Macrogenics Inc had $150M of revenue in fiscal 2025, down 0.3% on the year before. Over five years, revenue changed +7.3% a year on average. Its operating margin was β48.7%, up 25.0Β pts: of every 100 in sales, about β49 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Macrogenics Inc lost $74.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$83.0M in fiscal 2025, β55.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Macrogenics Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $123M | $109M | $101M | $183M | $57.2M |
| Interest coverage | β | β | β117.7x | β99.2x | β8.6x |
| Current ratio | 3.7x | 4.6x | 4.5x | 3.9x | 5.1x |
| Quick ratio | 3.7x | 4.5x | 4.5x | 3.9x | 4.9x |
| Total assets | $335M | $280M | $298M | $262M | $257M |
| Total liabilities | $95.6M | $138M | $146M | $146M | $201M |
| Shareholders' equity | $240M | $142M | $153M | $116M | $55.6M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Macrogenics Inc passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 7 | 1 / 7 | 4 / 7 | 4 / 8 | 1 / 8 | 5 / 8 | 2 / 8 | 2 / 8 | 3 / 8 |
| Accruals ratio | β4.8% | β9.9% | β5.2% | β5.4% | β5.2% | β16.3% | β10.7% | 23.9% | 0.5% | 2.5% |
| Altman Z'' | 7.68 | 5.87 | β1.29 | β3.47 | β0.68 | β6.89 | β10.49 | β10.44 | β12.52 | β12.89 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $91.9M | $158M | $60.1M | $64.2M | $105M | $77.4M | $152M | $58.7M | $150M | $150M |
| Gross profit | β | β | β | $64.2M | $105M | $74.8M | $149M | $58.1M | $149M | $150M |
| Research and development | $122M | $147M | $191M | $195M | $193M | $215M | $207M | $167M | $177M | $147M |
| Operating income | β$60.0M | β$22.1M | β$171M | β$177M | β$131M | β$203M | β$121M | β$168M | β$111M | β$72.8M |
| Interest expense | β | β | β | β | β | $0.0M | $0.0M | $1.4M | $1.1M | $8.5M |
| Pretax income | β | β | β | β | β | β | β$120M | β$9.1M | β$66.0M | β$75.3M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.9M | β$0.7M |
| Net income | β$58.5M | β$19.6M | β$171M | β$152M | β$130M | β$202M | β$120M | β$9.1M | β$67.0M | β$74.6M |
| Diluted EPS | β$1.69 | β$0.54 | β | β | β$2.47 | β$3.37 | β$1.95 | β$0.15 | β$1.07 | β$1.18 |
| Diluted shares | 0.03B | 0.04B | 0.04B | 0.05B | 0.05B | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| Cash flow | ||||||||||
| Cash from operations | β$43.7M | $14.4M | β$153M | β$134M | β$112M | β$144M | β$87.0M | β$78.2M | β$68.4M | β$81.0M |
| Capital expenditure | $11.4M | $29.4M | $25.0M | $4.3M | $5.9M | $6.2M | $3.6M | $1.8M | $3.7M | $1.9M |
| Free cash flow | β$55.1M | β$15.0M | β$178M | β$139M | β$118M | β$150M | β$90.6M | β$80.0M | β$72.1M | β$83.0M |
| Depreciation and amortization | $7.6M | $7.2M | $9.2M | $12.3M | $12.0M | $11.3M | $11.9M | $9.6M | $7.5M | $7.2M |
| Stock-based compensation | $12.2M | $14.7M | $16.5M | $19.6M | $20.7M | $23.1M | $20.4M | $18.4M | $29.4M | $14.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $84.1M | $212M | $220M | $126M | $181M | $123M | $109M | $101M | $183M | $57.2M |
| Current assets | $284M | $322M | $269M | $240M | $313M | $280M | $222M | $251M | $217M | $220M |
| Current liabilities | $27.3M | $49.8M | $59.9M | $45.2M | $50.7M | $74.6M | $48.6M | $56.1M | $55.5M | $43.1M |
| Inventory | β | β | β | β | $0.0M | $4.4M | $1.5M | $1.2M | $0.0M | $7.9M |
| Property and equipment, net | $18.0M | $50.0M | $56.7M | $48.2M | $42.2M | $37.7M | $29.6M | $21.8M | $18.1M | $2.1M |
| Total assets | $311M | $374M | $332M | $313M | $379M | $335M | $280M | $298M | $262M | $257M |
| Total liabilities | $42.5M | $74.6M | $89.3M | $81.9M | $82.9M | $95.6M | $138M | $146M | $146M | $201M |
| Shareholders' equity | $269M | $299M | $243M | $231M | $296M | $240M | $142M | $153M | $116M | $55.6M |
| Margins | ||||||||||
| Gross margin | β | β | β | 100.0% | 100.0% | 96.6% | 97.8% | 98.9% | 99.4% | 100.0% |
| Operating margin | β65.3% | β14.0% | β284.8% | β276.0% | β125.0% | β261.9% | β79.9% | β286.4% | β73.7% | β48.7% |
| EBITDA margin | β57.1% | β9.5% | β269.5% | β256.9% | β113.6% | β247.3% | β72.1% | β270.0% | β68.7% | β43.9% |
| Net margin | β63.7% | β12.4% | β285.2% | β236.5% | β123.7% | β261.0% | β78.8% | β15.4% | β44.7% | β49.9% |
| FCF margin | β59.9% | β9.5% | β296.4% | β215.9% | β112.3% | β193.7% | β59.6% | β136.1% | β48.1% | β55.5% |
| Returns | ||||||||||
| Return on capital employed | β21.1% | β6.8% | β62.9% | β66.3% | β39.9% | β77.8% | β52.4% | β69.4% | β53.6% | β34.1% |
| Return on equity | β21.8% | β6.9% | β63.3% | β64.1% | β49.3% | β75.5% | β62.8% | β6.1% | β49.9% | β86.9% |
| Return on assets | β18.8% | β5.7% | β48.6% | β47.1% | β37.5% | β56.6% | β38.9% | β3.1% | β23.9% | β28.8% |
| Return on tangible equity | β21.8% | β6.6% | β70.6% | β65.8% | β43.8% | β84.3% | β84.3% | β5.9% | β57.7% | β134.2% |
| Growth | ||||||||||
| Revenue growth | β | 71.7% | β61.9% | 6.8% | 63.4% | β26.2% | 96.2% | β61.3% | 155.3% | β0.3% |
| Share count change | β | 4.1% | 13.4% | 17.5% | 9.1% | 14.3% | 2.5% | 0.8% | 1.1% | 0.9% |
| Financial health | ||||||||||
| Interest coverage | β | β | β | β | β | β | β | β117.7x | β99.2x | β8.6x |
| Current ratio | 10.4x | 6.5x | 4.5x | 5.3x | 6.2x | 3.7x | 4.6x | 4.5x | 3.9x | 5.1x |
| Quick ratio | 10.4x | 6.5x | 4.5x | 5.3x | 6.2x | 3.7x | 4.5x | 4.5x | 3.9x | 4.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 12.4% | 18.6% | 41.5% | 6.7% | 5.6% | 8.0% | 2.4% | 3.0% | 2.5% | 1.3% |
| Stock comp / revenue | 13.2% | 9.3% | 27.5% | 30.5% | 19.7% | 29.9% | 13.5% | 31.3% | 19.6% | 9.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 1.0 | 4.0 | 4.0 | 1.0 | 5.0 | 2.0 | 2.0 | 3.0 |
| Altman Z'' | 7.7 | 5.9 | β1.3 | β3.5 | β0.7 | β6.9 | β10.5 | β10.4 | β12.5 | β12.9 |
| Accruals ratio | β4.8% | β9.9% | β5.2% | β5.4% | β5.2% | β16.3% | β10.7% | 23.9% | 0.5% | 2.5% |
Source: SEC EDGAR XBRL filings (CIK 0001125345). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
